CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 141 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2016. The put-call ratio across all filers is 1.05 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $498,000 | -85.8% | 174,129 | -87.7% | 0.00% | -84.6% |
| Q2 2017 | $3,501,000 | -37.0% | 1,417,236 | -7.9% | 0.03% | -36.6% |
| Q1 2017 | $5,554,000 | +0.2% | 1,538,449 | -1.7% | 0.04% | -4.7% |
| Q4 2016 | $5,543,000 | -14.6% | 1,565,694 | -2.6% | 0.04% | -17.3% |
| Q3 2016 | $6,493,000 | -20.5% | 1,607,068 | -13.6% | 0.05% | -22.4% |
| Q2 2016 | $8,164,000 | +1.0% | 1,859,772 | -13.0% | 0.07% | +4.7% |
| Q1 2016 | $8,084,000 | -77.9% | 2,138,708 | -8.4% | 0.06% | -78.9% |
| Q4 2015 | $36,624,000 | -0.7% | 2,335,689 | -33.2% | 0.30% | -2.3% |
| Q3 2015 | $36,876,000 | -41.4% | 3,498,712 | +40.2% | 0.31% | -31.4% |
| Q2 2015 | $62,945,000 | +244.0% | 2,495,832 | +280.2% | 0.45% | +242.4% |
| Q1 2015 | $18,298,000 | -15.1% | 656,534 | -44.4% | 0.13% | -17.0% |
| Q4 2014 | $21,546,000 | +73.6% | 1,180,618 | +23.3% | 0.16% | +59.0% |
| Q3 2014 | $12,413,000 | -17.6% | 957,806 | +3.8% | 0.10% | -9.9% |
| Q2 2014 | $15,062,000 | – | 922,891 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TSP Capital Management Group, LLC | 813,273 | $3,286,000 | 1.66% |
| RTW INVESTMENTS, LP | 1,243,164 | $5,022,000 | 1.52% |
| Marcus Capital, LLC | 112,200 | $453,000 | 0.44% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 996,178 | $4,024,000 | 0.29% |
| Benchmark Capital Advisors | 67,000 | $271,000 | 0.20% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 360,299 | $1,456,000 | 0.20% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 2,907,523 | $11,746,000 | 0.15% |
| Virtus ETF Advisers LLC | 59,537 | $241,000 | 0.12% |
| Bellevue Group AG | 160,000 | $646,000 | 0.12% |
| PDT Partners, LLC | 428,300 | $1,730,000 | 0.10% |